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A B S T R A C T   
Current treatment for corneal endothelial dysfunction consists in the replacement of corneal endothelium by 
keratoplasty. Owing to the scarcity of donor corneas and the increasing number of transplants, alternative 
treatments such as cell-based therapies are necessary. In this article, we highlight the biological aspects of the 
cornea and the corneal endothelium, as well as the context that surrounds the need for new alternatives to 
conventional keratoplasty. We then review some of those experimental treatments in more detail, focusing on the 
development of the in vitro and preclinical phases of two cell-based therapies: tissue-engineered endothelial 
keratoplasty (TE-EK) and cell injection. In the case of TE-EK graft construction, we analyse the current progress, 
considering all the requirements it must meet in order to be functional. Moreover, we discuss the inherent 
drawbacks of endothelial keratoplasties, which TE-EK grafts should overcome in order to make surgical inter-
vention easier and to improve the outcomes of current endothelial keratoplasties. Finally, we analyse the 
development of preclinical trials and their limitations in terms of performing an optimal functional evaluation of 
cell-based therapy, and we conclude by discussing early clinical trials in humans.   
1. Introduction 
The cornea is the first eye lens that participates in light refraction 
onto the retina, allowing for the collection of visual information from 
the external environment. The internal organization of its components, 
together with its avascularity, provides the physical basis for that 
function. Among its main corneal layers (epithelium, stroma and 
endothelium), the stroma is the most important one from an optical 
point of view. This layer accounts for two thirds of the total refractive 
power of the eye and is mainly composed of overlapping lamellae 
constituted of collagen I and proteoglycans, which attract water from 
the aqueous humor. In normal stromal deturgescence conditions, i.e. in a 
relative state of stromal dehydration, the homogeneous collagen fiber 
arrangement confers the required transparency and curvature for vision. 
However, the stroma cannot properly fulfill that role without the 
endothelium, which controls stromal dehydration and, therefore, en-
sures the correct distance among stromal collagen fibers to maintain 
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corneal features (Meek and Knupp, 2015). 
If endothelium fails, vision can be impaired and, in severe cases, 
surgical intervention may be required to replace the damaged tissue 
with a new one by keratoplasty. Here, we review some alternative 
treatments for endothelial dysfunction, which otherwise often ends in 
corneal or endothelial transplantation. We particularly focus on the 
development of two cell-based therapies: cell injection (CI) and tissue- 
engineered endothelial keratoplasty (TE-EK), considering the biolog-
ical and functional aspects of the endothelium and the cornea. 
Regarding TE-EK, we analyse the engineered graft keeping in mind the 
drawbacks of conventional endothelial keratoplasty, which this future 
treatment should match or exceed, and we conclude by providing an 
overview of clinical trials, which come into play to assess the actual 
value of these new treatments. 
1.1. Corneal endothelium: function, aging and disease 
Corneal endothelium is constituted by hexagonal-like endothelial 
cells (ECs) that form a packed cell monolayer on a specialized basal 
membrane called Descemet membrane (DM). A strong cohesion among 
ECs is generated via adhesion complexes mainly formed by adherens 
junctions, localized to the lateral-basal membrane, and tight junctions, 
localized to the lateral-apical membrane (He et al., 2016b). Tight 
junctions make it possible for the endothelium to play the role of a leaky 
barrier, as they control transmembrane circulation of molecules such as 
bicarbonate ions, sodium, chloride and glucose between the aqueous 
humor and the stroma (Bonanno, 2012; Srinivas, 2012), together with 
different transporters, such as the Na+/K+ ATPase pump and the sodium 
bicarbonate cotransporter, which counteract the flux of water into the 
stroma by pumping ions and other solutes into the aqueous humor. Thus, 
the endothelium, as a leaky-pump barrier, keeps the water content of the 
stroma at adequate levels so that it remains transparent (Bonanno, 2012; 
Edelhauser, 2006; Srinivas, 2012). 
Human ECs (hECs) show a limited capacity for division in vivo. They 
are mostly arrested in phase G1 of the cell cycle, and a decrease in 
proliferation potential from the periphery to the central part of the 
cornea can be observed (Joyce, 2012; Joyce et al., 1996; Mimura and 
Joyce, 2006; Senoo and Joyce, 2000). Without the possibility to replace 
dead ECs, endothelial cell density (ECD) decreases at a rate of 0.3% per 
year, with an average ECD around 3000 cells/mm2 in adult individuals 
(Hollingsworth et al., 2001). Thus, the strategies used by the endothe-
lium to maintain a functional cell monolayer are cell migration and 
contiguous cell spread (Matsuda et al., 1985). Due to this, the adult 
endothelium appears as a sheet of cells distributed following a cobble-
stone pattern generated by variations in shape (pleomorphism) and size 
(polymegathism) (Hollingsworth et al., 2001). 
If the rate of EC loss is unusually high and ECD decreases down to 
values below a threshold of approximately 500 cells/mm2, the endo-
thelium cannot execute its function properly, subsequently leading to 
corneal edema, visual impairment and even blindness (Mishima, 1982). 
This extreme situation can be observed, for example, in endothelia 
affected by Fuchs’ endothelial dystrophy (FED). FED has an estimated 
prevalence of 4–9% in some American and European regions and 3–7% 
in Asian regions (Soh et al., 2019). This dystrophy normally begins at 
middle age and progressively develops for years. Signals of FED consist 
of fast ECD decrease, changes in ECs morphology and formation of 
guttae in DM (Feizi, 2018; Soh et al., 2019). In its later stages, endo-
thelial decompensation can result in epithelial bullae as a consequence 
of stromal edema (Eghrari et al., 2015). The presence of epithelial bullae 
can also be due to endothelial trauma caused, for example, during 
intraocular surgeries such as cataract extraction and can lead to bullous 
keratopathy (BK). Elderly individuals are the ones who most frequently 
develop BK as a consequence of trauma (Feizi, 2018). 
1.2. Corneal transplant for endothelial decompensation 
Corneal transplant is the conventional treatment for irreversible 
endothelial decompensation (Feizi, 2018). In the 20th century, trans-
plantation of the full-thickness cornea, or penetrating keratoplasty (PK), 
was the gold standard procedure; however, nowadays, endothelial ker-
atoplasty (EKs) disputes their place as the surgery of choice for 
providing a healthy endothelium for visual recovery. EK consists in the 
selective replacement of injured endothelium without substituting the 
remaining, non-damaged corneal layers. Among the different types of 
EK, Descemet stripping automated endothelial keratoplasty (DSAEK) 
(Gorovoy, 2006; Price and Price, 2006) and Descemet membrane 
endothelial keratoplasty (DMEK) (Melles et al., 2002) are the most 
successful and widely performed. In DSAEK, the graft consists of a 
curved cut from the donated posterior cornea with a thin piece of 
stroma. In DMEK, the replacement is structurally more exact, as the graft 
is only composed of endothelium on DM. In both cases, the graft is 
inserted after descemetorhexis (DM-endothelium removal) (Maharana 
et al., 2017). 
The obvious transition from PK to EK in developed countries 
(Flockerzi et al., 2018; Nishino et al., 2019; Park et al., 2015) is widely 
justified by the benefits of EK over PK. EK is less invasive and allows 
maintaining the structural integrity of the eyeball while avoiding the 
complications associated with open-sky PK, including sutures and in-
fections (Boynton and Woodward, 2015). Moreover, the reduction or 
absence of stroma minimizes the risk of a graft rejection episode, as the 
graft contains fewer antigen-presenting cells (Hos et al., 2019). 
Furthermore, patient visual acuity recovery is better and more quickly 
achieved after EK than after PK (Boynton and Woodward, 2015). All 
these advantages greatly compensate for the main drawbacks of EK. 
These are related to the highly demanding DSAEK and DMEK tech-
niques, whose correct performance entails a long and difficult learning 
curve due to the issues associated with graft handling. Severe graft EC 
loss, detected during the early postsurgical period within one, six, or 
twelve months after surgery and also described for PK (Ku et al., 2017; 
Price et al., 2016; Woo et al., 2019), has also been reported as a 
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disadvantage of EK, along with graft detachment. Moreover, EK is not 
free of refractive aberrations due to irregularities in the graft or the 
host-graft interface, although they are less severe and more predictable 
than in the case of PK (Boynton and Woodward, 2015; Price et al., 
2017). However, all these disadvantages have been partially solved by 
using grafts with high ECD, improving surgical techniques and devel-
oping new instruments for specific keratoplasty steps. Among these are 
the improvement of the graft collection process (Parekh et al., 2017), the 
use of graft-insertion devices minimize graft handling (Khor et al., 2011; 
Soma et al., 2019), and easy re-attachment approaches in case of graft 
detachment (Parekh et al., 2018a). 
The safety and excellent results of EK, together with the aging of the 
population and the subsequent increase in late-onset eye diseases such 
as cataracts or glaucoma, whose treatments can lead to endothelial 
damage (Feizi, 2018), encourage surgeons and patients to perform this 
surgery at earlier stages of endothelial dysfunction (Flockerzi et al., 
2018). This situation leads to an imbalance between the increasing 
number of corneal transplants and the current stock of donated cadav-
eric corneas, the raw material for all types of keratoplasty (Gain et al., 
2016). For EK, the graft is excised from a cornea with high-quality 
endothelium. Considering donor selection criteria (European Direc-
torate for the Quality of Medicines and Healthcare, 2017) and the 
decrease in ECD with aging, compliance with all the requirements for EK 
grafts is difficult to achieve. 
2. Experimental treatments for endothelial decompensation 
Several alternatives to conventional PK or EK have been proposed for 
the treatment of endothelial dysfunction. These experimental therapies 
aim to regenerate the corneal endothelium using different methods and 
are currently in different states of development and understanding. 
Here, we classify them according to the origin of the ECs used to 
regenerate the endothelium. 
2.1. Treatments with autologous ECs 
Descemetorhexis without endothelial keratoplasty (DWEK) (Gar-
cerant et al., 2019) and acellular DM transplantation (Soh and Mehta, 
2018) are experimental treatments based on the migration and 
enlargement capacity of hECs in vivo. Hence, after these surgeries, host 
ECs located in the endothelial periphery should migrate centripetally 
and either cover the bare stroma generated by DWEK or colonize the 
transplanted denuded DM. Sometimes, DWEK is combined with the 
administration of a rho-associated protein kinase (ROCK) inhibitor 
(ROCKi) formulated as eye drops to promote endothelial regeneration 
(Garcerant et al., 2019). The ROCKi protein family has shown positive 
modulation of EC migration and cell cycle and has been demonstrated to 
promote cell adhesion (Okumura et al, 2009, 2017) and to contribute to 
the conservation of a normal EC morphology and phenotype (Okumura 
et al, 2012, 2017). The huge potential of ROCKi has not only been used 
in this type of alternative treatments, but also in cell-based therapies 
(Okumura et al., 2017), which are later reviewed in section 2.2.2. as well 
as in the form of experimental eye drops to treat certain endothelial 
dysfunctions (Okumura et al., 2013). 
Considering the low number of studies on DWEK and acellular DM 
transplantation, as well as other clinical cases related to in vivo endo-
thelium regeneration after a failed EK, some authors have suggested the 
possibility of a certain degree of hEC division, which could explain the 
improvements in endothelial cell density and in visual acuity of patients 
(Van den Bogerd et al., 2018a). Nonetheless, the relative success of these 
treatments varies among patients and among clinical case reports, and it 
is higher in the case of FED due to the presence of a large cell reservoir at 
the periphery, which is sometimes lacking in BK (Garcerant et al., 2019; 
Soh and Mehta, 2018). Further research is needed to understand this 
variability in the results and to turn DWEK and DM transplantation into 
reliable treatments for endothelial decompensation. 
2.2. Treatments with allogenic sources of ECs 
Cell-based therapies that use allogenic ECs are the most developed 
and, consequently, the most promising experimental treatments for 
endothelial decompensation compared with the above-mentioned 
treatments. These include cell injection (CI) for in vivo formation of 
endothelium and tissue engineering (TE) for in vitro construction of EK 
grafts. 
2.2.1. Cell sources for cell-based therapies 
The collection of a sufficient number of hECs to be used in cell-based 
therapies must avoid any ethical issues and guarantee the safety of the 
engrafted patient. At present, these premises reduce the possibility of 
employing three unlimited hEC sources: embryonic stem cells, induced 
pluripotent stem cells (iPSc) and immortalized hECs. While the first one 
involves the destruction of an embryo, which is ethically questionable, 
both iPS and immortalized cells are linked to tumorigenesis (Maqsood 
et al., 2013; Yoshihara et al., 2017) in relation to the genetic reprog-
ramming used to generate them. 
Endothelial progenitor cells (EPCs) represent a cell source with a 
certain capacity for division. EPCs have been suggested to be present in 
Schwalbe’s line at the endothelial periphery and/or in the trabecular 
meshwork. These hypotheses are supported by the expression of stem, 
neural crest and proliferation markers in cells from those areas; by the 
capacity of these cells to form spheres under culture conditions, which is 
characteristic of neural crest-derived cells with proliferative abilities; 
and by successful endothelial differentiation assays (Hara et al., 2014; 
Katikireddy et al., 2016; McGowan et al., 2007; Mimura et al., 2010; 
Yam et al., 2019; Yokoo et al., 2005; Zhang et al., 2018). With respect to 
the use of these cell sources for cell-based therapies, Mimura et al. 
employed sphere-forming progenitor cells for CI therapy, while Hara 
et al. used progenitor cell-derived ECs to build an endothelial graft using 
atelocollagen as a carrier; both were used in an animal model with 
considerable success (Hara et al., 2014; Mimura et al., 2005b, 2005c). 
However, as far as we know, this source of ECs has not been further used 
in any other cell-based therapy studies, probably because of their het-
erogeneous proliferative potential, which in turn is due to the regulation 
of pathways related to their cell differentiation process (Hir-
ata-Tominaga et al., 2013), to donor age (Hara et al., 2014) or to other 
donor-related variables. Further efforts are clearly warranted to under-
stand the mechanisms of migration and differentiation of EPCs and to 
characterize them, as well as to develop an effective protocol for their 
isolation and expansion that can provide ECs for cell-based therapies 
(Sie et al., 2020). 
Primary hECS, obtained directly from corneal endothelium, are the 
most commonly used type of cells in TE and CI therapy studies. For this 
purpose, basic research has provided the knowledge required for hEC 
isolation and culture, as well as for the progressive understanding of 
their biology both in vivo and in vitro. Thus, by using culture media 
supplemented with serum and mitogenic factors that force hEC division 
(Fig. 1), a sufficient number of cells with the desirable properties of hECs 
can be obtained (Soh et al., 2016). These properties are, on one hand, an 
adequate hexagonal morphology and, on the other, endothelial bio-
markers, such as the typically used ZO-1 of tight junctions and Na+/K+
ATPase, among others, whose expression and protein cytolocalization 
resemble that of the in vivo phenotype of hECs (Frausto et al., 2016; He 
et al., 2016b). 
Nevertheless, primary hECs are not free of limitations. They can 
dedifferentiate in culture, lose their recognizable biomarkers and ac-
quire a mesenchymal-like morphology and phenotype, frequently after 
the third passage (Peh et al., 2011). This change occurs within a process 
known as endothelial-mesenchymal transition (EMT) (Roy et al., 2015), 
which renders these hECs invalid for cell-based therapies and thus re-
duces the possibility of obtaining a large amount of cells from a single 
donor. Moreover, variability among donors can lead to a reduction in the 
number of acceptable hECs because even if cells have been cultured 
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under similar conditions, they can behave differently due to, for 
example, the donor’s age or health condition (Soh et al., 2016). 
At present, the best available source of primary hECs is found in eye 
banks. On one hand, healthy endothelium from donated corneas dis-
carded either due to pathologies in other corneal layers or to low ECD 
can be used for hEC isolation and culture. On the other hand, the 
endothelial periphery that remains in a donated cornea after trephina-
tion for PK, as proposed by Vázquez et al. (2016), or after stripping the 
central area of the DM-endothelium complex for DMEK could be recy-
cled for the same purpose. 
2.2.2. Cell injection for in vivo endothelium regeneration 
Comparing CI and TE, CI is the less invasive and less technically 
demanding treatment. In addition, the in vitro phase of CI therapy is 
short, as it only requires the expansion of hECs. A suspension of these 
cells in a vehicle solution is then injected into the anterior chamber. This 
constitutes another advantage of CI over TE, as CI does not require the 
presence of a carrier. Conversely, TE graft transplantation requires a 
carrier, which could affect light refraction and visual acuity, as 
explained below. In CI, hECs should adhere to the inner surface of the 
cornea, which can be either empty stroma or acellular DM. The presence 
of DM seems to lead to better results (Xia et al., 2019), which suggests 
that this therapy could be limited to those endothelial dysfunctions with 
a healthy DM, such as some BK cases, while it could not be used, for 
example, in late-stage FED. 
One of the crucial points of CI is the control of the amount and fate of 
injected ECs, because excess or non-adhered cells could obstruct 
trabecular meshwork and, in a worst-case scenario, could block the 
outflow of aqueous humor, consequently elevating intraocular pressure 
(IOP). Moreover, those cells could deposit ectopically in other tissues of 
the eye or body (Mimura et al., 2003). To ensure correct cell disposition, 
the simplest technique for leading ECs to the inner surface is by gravity, 
with the engrafted host adopting a prone position after cell injection, 
thus allowing for cell adhesion (Mimura et al., 2007). Several 
researchers have demonstrated that endocytosis of non-cytotoxic con-
centrations of iron particles (Mimura et al, 2003, 2005a) or super-
paramagnetic microspheres (Patel et al., 2009; Xia et al., 2019) during 
the in vitro phase of CI therapy helped lead ECs to the recolonization 
area, either using a magnet to attract them in combination with gravity 
(Xia et al., 2019) or not (Mimura et al, 2003, 2005a). 
Additionally, to enhance cell adhesion, ROCKi Y-27632 is usually 
added to the EC suspension for cell injection (Table 1). With this sup-
plement, the correct expression of EC functional biomarkers and the 
normal hexagonal-like morphology has also been observed to improve 
and yielded substantially better outcomes in preclinical studies (Oku-
mura et al., 2016b). 
2.2.3. Tissue engineering of an EK graft 
TE offers the possibility of creating EK grafts with customized 
characteristics, which could be used for all types of endothelial de-
compensations. Tissue-engineered EK (TE-EK), with ECD values above 
the eye banks’ thresholds for EK surgeries, could replace conventional 
EK by maintaining and simplifying the well-known EK surgical tech-
nique while matching or exceeding its patient outcomes. Considering 
the drawbacks of EK (as discussed in section 1.3.), which can summarize 
as difficult graft handling, graft detachment, initially detected severe EC 
loss and refractive aberrations, tissue engineering should solve or reduce 
these complications. 
Building a TE-EK graft requires a biocompatible carrier for the re-
generated endothelium. Endothelium can be developed directly on said 
carrier or be transferred to it after its formation on a different surface, 
such as a thermo-responsive plastic (Lai et al., 2015). Carriers whose 
composition is essentially collagen, such as corneal stromal lamellae 
(Arnalich-Montiel et al., 2019; He et al., 2016a; Peh et al, 2017, 2019), 
basal cell membranes (Liu et al., 2019; Van den Bogerd et al., 2018b), 
fish scales (Parekh et al., 2018b) and collagen or collagen-derived sheets 
(Li et al., 2017; Vázquez et al., 2016), have been the most extensively 
tested in vitro and/or in animal models, together with carriers of other 
Fig. 1. Example of the workflow of an in vitro phase of tissue engineered-endothelial keratoplasty (TE-EK) therapy. Donor cornea is excised from an eyeball (A). The 
Descemet membrane-endothelium complex is manually peeled off (B) and incubated with collagenase or other enzymes for endothelial cell (EC) isolation (C). ECs are 
expanded (D), and an adequate number of cells is seeded on a flat thin transparent carrier, previously functionalized with a coating to enhance cell adhesion and 
proliferation (E). ECs on the carrier are cultured to allow for the formation of a tightly packed endothelium. Quality control of the process is performed to ensure the 
adequate hexagonal morphology of cells at the end of culture (F, right) and expression of EC biomarkers, such as those that participate in the cell-cell adhesion 
complex, which would be cytolocalizable to their membranes (F, left). The engineered graft is transplanted using the current EK techniques to restore the visual 
acuity of a patient (G). 
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materials such as silk fibroin (Vázquez et al., 2017) or synthetic poly-
mers (Kim et al., 2017; Kruse et al., 2018; Salehi et al., 2017). 
Nonetheless, not all these carriers are valid to engineer an EK graft, 
as several physical properties are required to ensure functional endo-
thelium regeneration and correct vision. The characteristics of these 
carriers can sometimes be complemented by culture techniques that 
promote the formation of the endothelial layer. 
2.2.3.1. Carrier transparency, thickness and shape. Transparency is the 
first optical parameter intuitively sought in a carrier. However, it is not 
sufficient to guarantee correct visual acuity. Irregularities in carrier 
structure or in the junction between the host and the TE-EK graft can 
lead to refractive aberrations. To minimize them, thickness and shape 
should be controlled. 
According to clinical studies, thin grafts such as those used for DMEK 
decrease the probabilities of refractive aberrations (Dickman et al., 
2016). This supports the use of very thin carriers with thickness values 
close to those of DMEK grafts, as some research groups are currently 
attempting by using silk fibroin and collagen-derived sheets (Vázquez et 
al, 2016, 2017; Yoshida et al., 2017). 
As for shape, flat carriers could cause wrinkles when attached to the 
inner face of the cornea. However, carriers with a curvature similar to 
that of the host stroma could fit and adhere properly across its whole 
surface, thus decreasing the chance of graft detachment (Kimoto et al., 
2014) and fibrosis in wrinkled spaces, which would otherwise lead to 
refractive aberrations (Müller et al., 2016). Taking this issue into ac-
count, researchers gave a curved shape to their porcine atelocollagen 
(Yoshida et al, 2014, 2017), collagen I (Li et al., 2017) and gelatin 
carriers (Kimoto et al., 2014) or directly used decellularized corneal 
lamellae cut by femtosecond laser, the same method used to generate 
ultra-thin DSAEK grafts (Arnalich-Montiel et al., 2019; He et al., 2016a; 
Peh et al, 2017, 2019). 
2.2.3.2. Carrier strength, elasticity and permeability. Carriers should 
tolerate IOP and act as a structural barrier that allows molecules to cross 
between the stroma and the endothelium or the aqueous humor. For 
these purposes, they should have sufficient strength and elasticity, as 
well as a certain degree of permeability, without disrupting their 
structural internal organization. 
The two aforementioned mechanical properties are also involved in 
TE-EK graft handling. As the unfolding step in DSAEK is easier and faster 
than in DMEK, thanks to the slight rigidity that the stromal layer confers 
to grafts, the ideal TE-EK graft should have a strength and elasticity 
similar to those of DSAEK grafts, thus involving a shorter learning curve 
for surgeons (He et al., 2016a). These characteristics occur naturally in 
corneal stromal lamellae, as noted by several research groups (Arna-
lich-Montiel et al., 2019; He et al., 2016a; Honda et al., 2009; Peh et al, 
2017, 2019). Interestingly, some authors demonstrated the handle-
ability of their manufactured TE-EK grafts without carrying out a 
pre-clinical trial. They performed a simple but effective assay consisting 
in loading the constructed graft with the current EK graft insertion in-
struments, introducing it in an excised eyeball, and unfolding it (He 
et al., 2016a; Vázquez et al., 2015). 
2.2.3.3. Topography and hydrophilicity of carrier. Moving on to the in 
vitro step of endothelial regeneration, carriers should show high hy-
drophilicity to allow for initial cell adhesion, usually confirmed by a low 
contact angle of a water drop on its surface (Kim et al, 2015, 2017, 
2018). In addition, a slightly homogeneous rough topography promotes 
the development of a confluent and packed endothelium without gaps 
among cells (Muhammad et al., 2015; Rizwan et al., 2017). 
2.2.3.4. Functionalization of carriers. Functionalization of carriers with 
coatings is a culture technique used to improve EC adhesion and endo-
thelial regeneration (Fig. 1) (Arnalich-Montiel et al., 2019; Parekh et al., 
2018b; Salehi et al., 2017; Van den Bogerd et al., 2018b; Vázquez et al., 
2017). Coatings composed of proteins or glycoproteins, such as laminin, 
collagen or fibronectin, which normally constitute basal membranes 
such as DM, provide an increasing number of binding points for EC 
integrins. They are widely used in vitro for EC expansion (Okumura et al., 
2015; Peh et al., 2015). When using them, EC usually showed better 
expression of functional endothelial biomarkers and better EC 
morphology (Arnalich-Montiel et al., 2019; Okumura et al., 2015; 
Vázquez et al., 2017). Additionally, functionalization can be performed 
by incorporating other types of substances that promote cell prolifera-
tion and differentiation, such as β-carotene, to carrier surfaces (Kim 
et al., 2018). 
2.2.3.5. Bioreactors for endothelial regeneration. Endothelial regenera-
tion and TE-EK graft maturation are usually performed under static 
conditions and without pressure (Fig. 1). Several studies have developed 
perfusion devices that offer the possibility of recreating the physiolog-
ical corneal environment, adding pressure and an exchange rate of a 
medium simulating aqueous humor outflow in the cornea. Natural 
corneal conditions were demonstrated to improve expression of func-
tional biomarkers of ECs and their recognizable morphology (Li et al., 
2017; Thériault et al., 2019), thus providing excellent results for endo-
thelial regeneration on a collagen carrier for TE-EK (Li et al., 2017). 
Table 1 
Attempts for cell injection therapy in animal models. Thickness should be assessed relative to the normal (untreated) corneal thickness in the corresponding animal 
model, which is approximately 400 μm for rabbits, over 470 μm for monkeys and around 578 μm for cats. ECD: endothelial cell density; fEC: feline endothelial cells; 
hEC: human endothelial cells; mEC: monkey endothelial cells; N/A: no data available; rEC: rabbit endothelial cells; ROCKi: ROCK inhibitor; w/: with; w/o: without.   
Preclinical phase 
Reference Injected cells Animal Follow-up Final follow-up 
ECD (cells/mm2) Thickness (μm) Transparency 
Xia et al. (2019) Magnetic endocytosing rECs Rabbit 3 months N/A N/A Yes 
Peh et al. (2019) hEC w/ROCKi Rabbit 3 weeks 1409 ± 128 582.5 ± 171.5 Yes 
Okumura et al. (2018) rEC w/ROCKi Rabbit 2 weeks 1602 ± 241 <600 Yes 
Okumura et al. (2016b) mEC w/and w/o ROCKi Monkey 1 year >2000 (w/ROCKi) ~600 Yes 
hEC w/and w/o ROCKi Monkey 3 months 2890 (w/ROCKi) ~850 Yes 
Okumura et al. (2016a) rEC w/ROCKi Rabbit 2 weeks >2000 ~400 Yes 
Bostan et al. (2016) fEC w/ROCKi Cat 1 month 1015 781 Yes 
Okumura et al. (2012) mEC w/ROCKi Monkey 3 months 2208 <600 Yes 
rEC w/ROCKi Rabbit 2 weeks N/A 409 Yes 
Mimura et al. (2005c) Spheres w/progenitor cells of hEC Rabbit 3 weeks 2781 ± 92 394 ± 26 Yes 
Mimura et al. (2005b) Spheres w/progenitor cells of rEC Rabbit 3 weeks 2963 ± 302 ~450 - 350 Yes 
Mimura et al. (2005a) Iron-endocytosing rEC Rabbit 12 months 2581 ± 230 407 ± 11 Yes 
Mimura et al. (2003) Iron-endocytosing rEC Rabbit 5 weeks N/A ~500 - 400 Yes  
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2.2.4. Preclinical trials on cell-based therapies 
In recent years, numerous research groups have tested their designed 
TE-EK grafts in animal models, while additional studies on CI therapy 
have been carried out (briefly summarized in Tables 1 and 2). These 
studies share some particularities in terms of their performance and 
evaluation. 
2.2.4.1. Animal models. The selection of an animal model for preclinical 
trials is significant, as those animals should be as close to humans as 
possible to allow extrapolating results. Thus, some researchers have 
carried out their preclinical trials on cats (Bostan et al., 2016) and 
monkeys (Koizumi et al., 2008; Okumura et al, 2012, 2016b), whose 
corneal and/or corneal endothelial characteristics are the most compa-
rable to those of humans (Proulx and Brunette, 2012). However, these 
have been a minority, while the use of rabbits has been notable. The 
tendency to use this rodent model is explained by the fact that rabbits 
are small, manageable and affordable (Proulx and Brunette, 2012). 
Nevertheless, they show several drawbacks, such as their narrow ante-
rior chamber, which complicates TE-EK graft testing (Yoshida et al., 
2017) and requires training to perform the surgery, and the fast in vivo 
division of rabbit ECs (rECs) (Van Horn et al., 1977). One strategy that 
has been thoroughly employed to reduce the likelihood of host rEC di-
vision and migration to the engrafted area of the cornea consists in 
limiting the duration of the assessment to 2–6 weeks (Peh et al., 2019) 
(Tables 1 and 2). However, this strategy prevents the generation of 
long-term results. Hsiue et al. and Lai et al. supplied a mitosis inhibitor 
(mitomycin-C) to the transplanted cornea (Hsiue et al., 2006; Lai et al, 
2007, 2015) to prevent any EC growth and, therefore, to allow pro-
longing follow-up for several months. 
Regardless of the selected animal model, EC labeling with cell 
trackers such as quantum dots (Toda et al., 2019) or membrane fluo-
rescent dies (Bostan et al., 2016; Okumura et al., 2016b; Yoshida et al., 
2017) before injection or keratoplasty is a widely used technique to 
verify the origin of ECs. Thus, it is possible to confirm that ECs in the 
engrafted area are those incorporated by the selected cell-based therapy 
rather than host ECs, as well as to ensure that injected ECs are not 
deposited on any other structure within the eyeball. With the same aim, 
Xia et al. used transduced ECs, which express green fluorescent protein, 
for CI therapy; similarly, Peh et al. carried out an immunofluorescence 
assay with a human-specific nuclei antibody on the endothelium of the 
excised TE-transplanted cornea (Peh et al., 2017; Xia et al., 2019). 
2.2.4.2. Functional evaluation of therapy and endothelium. During and 
after the follow-up period of cell-based therapy, several clinical pa-
rameters are usually recorded to provide information about the overall 
functionality of the treatment. Thickness and transparency, both related 
to each other, are the most important ones, although measuring IOP in 
CI therapy is required to ensure the lack of presence of cells in the 
trabecular meshwork (Bostan et al., 2016; Okumura et al., 2018; Xia 
et al., 2019). Immediately after the intervention, an increase in corneal 
thickness due to stromal edema and a loss of transparency are observed. 
If the treatment succeeds and the regenerated endothelium accom-
plishes its role, the cornea should become thinner and more transparent 
after a few days, and its final thickness should be as close as possible to 
that of a healthy non-transplanted cornea of the animal model. For 
example, the ideal engrafted corneal thickness should be around 400 μm 
in rabbits (Chan et al., 1983) and around 470 μm for primates (Zurawski 
et al., 1989), while for cats, thickness should be approximately 578 μm 
(Gilger et al., 1993). Despite the short follow-up periods, many re-
searchers have succeeded in achieving the normal corneal thickness of 
Table 2 
Attempts for tissue-engineered endothelial keratoplasty in animal models. Research was limited to those carriers that have been tested in pre-clinical trials using EK 
techniques or, in the case of those marked by an asterisk (*), using the predecessor of EK: deep lamellar endothelial keratoplasty. Thickness should be assessed relative 
to the normal (untreated) corneal thickness of the corresponding animal model, which is approximately 400 μm for rabbits and approximately 470 μm for monkeys. 
DM: Descemet membrane; ECD: endothelial cell density; hEC: human endothelial cells; mEC: monkey endothelial cells; N/A: no data available; PCL: polycaprolactone; 
PEG: poly(ethylene glycol); rEC: rabbit endothelial cells; sEC: sheep endothelial cell; w/: with.   
In vitro phase Preclinical phase 
Reference Carrier Cells ECD (cells/ 
mm2) 






Peh et al. (2019) Human decellularized stromal 
lamella 
hEC N/A Rabbit 3 weeks 1248 ± 64 484.3 ±
73.7 
Yes 
Arnalich-Montiel et al. 
(2019) 
Human decellularized stromal 
lamella w/FNC coating® 
hEC 2300 Rabbit 4 weeks N/A 747 Relative 
Kim et al. (2018) Bovine decellularized amniotic 
membrane 
RNase 5 vector- 
transfected hEC 
1244 Rabbit 4 weeks N/A 426.3 ±
153.9 
Yes 
Yoshida et al. (2017) Porcine atelocollagen hEC N/A Rabbit 2 weeks N/A 997.3 ±
134.9 
Relative 
Vázquez et al. (2017) Fibroin silk w/FNC coating® rEC N/A Rabbit 6 weeks N/A 366 Yes 




2680 ± 438 
Rabbit 3 weeks 1321 ± 23 517.3 ±
151.3 
Yes 
Vázquez et al. (2016) Human collagen I rEC N/A Rabbit 6 weeks N/A Close to 
native 
Yes 
Lai et al. (2015) Hyaluronic acid rEC 3289 ± 70 Rabbit 4 weeks 3216 ± 95 412.7 ±
25.0 
Yes 
Hara et al. (2014) Atelocollagen Progenitor-derived 
hEC 
N/A Rabbit 4 weeks 2263 ±
215 
369 Yes 
Ozcelik et al. (2014) PEG + hydrogel + PCL sEC 3150 ± 459 Sheep 4 weeks N/A N/A Yes 
Kimoto et al. (2014) Gelatin (collagen-derived) w/ 
atellocolagen coating 
mEC 2944 ± 350 Monkey 4 weeks 2300 ±
100 
>700 Yes 
Honda et al. (2009) Stromal lamella hEC 1656 Rabbit 4 weeks N/A 776 Yes 
(Koizumi et al, 2007, 
2008) 
Collagen I (Vitrigel) mEC 2240 ±
30.9 







(Lai et al., 2007)* Degradable gelatin (collagen- 
derived) 
hEC 2587 ± 272 Rabbit 6 months N/A 504.4 ±
24.7 
Yes 
Hsiue et al. (2006) Gelatin (collagen-derived) hEC ~2500 Rabbit 3 months N/A N/A Yes 
(Mimura et al., 2004)* Collagen I sheet hEC N/A Rabbit 4 weeks 2531 ±
290 
~400 Mild opacity  
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their animal model (Kim et al., 2018; Lai et al., 2015; Okumura et al., 
2016a; Vázquez et al., 2017). 
The quality and functionality of the regenerated endothelium at the 
end of the follow-up period must also be assessed. Some researchers 
have used the ECD parameter for this purpose. An ECD over the endo-
thelium function impairment threshold indicates a correct endothelial 
function, which is related to the recovery of transparency and relatively 
normal thickness of the treated cornea. In the case of TE-EK, some au-
thors have recorded graft ECD before and after transplantation, which 
provides information about initially detected severe EC loss caused by 
the intrinsic characteristics of the surgical technique, which is one of the 
main problems of EKs, as explained in section 1.3 above (Kimoto et al., 
2014; Koizumi et al, 2007, 2008; Lai et al., 2015; Peh et al., 2017). 
Likewise, corneal and endothelial evaluation is performed on excised 
engrafted corneas using histological techniques, e.g. basic staining 
techniques such as alizarin red, Masson’s trichrome staining, electron 
microscopy or immunofluorescence. These are usually employed to 
observe the morphology and/or expression of functional biomarkers of 
ECs such as ZO-1, N-cadherin or Na+/K+ ATPase and, in the case of 
TE-EK, to provide information about graft adhesion to the recipient 
cornea (Arnalich-Montiel et al., 2019; Kim et al., 2018; Okumura et al., 
2016b; Peh et al, 2017, 2019; Vázquez et al, 2016, 2017; Xia et al., 2019; 
Yoshida et al., 2017). 
With respect to visual acuity experiments, while they could provide 
information about possible refractive aberrations, they are generally 
overlooked in preclinical trials. This is understandable because the most 
commonly used animal model is rabbit, on which the test required to 
assess visual acuity cannot be performed, as they are not usually trained 
to focus on a target to measure aberrations. Furthermore, their optical 
aberrations are different from those found in the human cornea and 
would therefore be difficult to extrapolate (Chen et al., 2014). 
2.2.5. Clinical trials of cell-based therapies 
Although preclinical trials can be successful, the possibility of of-
fering a real alternative treatment for endothelial decompensation can 
only be supported by optimal results from clinical trials. This entails 
guaranteeing quality and patient safety across the whole TE-EK and CI 
procedure. All the steps of TE-EK graft construction and CI injection 
preparation, from the in vitro phase to the intervention itself, must 
comply with good manufacturing practices (GMP) and with regional 
quality and safety regulations and guidelines for the clinical use of cell- 
based therapies. The current common protocols for EC culture do not 
fulfill these requirements, since they use animal-derived materials, 
which could cause xenorejection or infection with animal pathogens. 
Therefore, Peh et al. reformulated their culture protocol for TE-EK, 
testing different substitutes to replace animal-derived serum and coat-
ings (Peh et al., 2019). Okumura et al. created a new vehicle solution for 
CI to avoid injecting culture media into the patient’s eyeball (Okumura 
et al., 2016a). 
Once safety and quality can be ensured, it is necessary to verify the 
efficacy of the new treatment, which should be equal to or better than 
that of the standard treatment. So far, only one clinical trial on CI 
therapy has been initiated by Kinoshita et al. The initial results after a 
two-year period showed a recovery of transparency and normal thick-
ness, as well as an improvement in visual acuity in some patients 
(Kinoshita et al., 2018). Regarding tissue engineering, the preclinical 
trials by Peh et al. (Peh et al, 2017, 2019) will be followed by the first 
approved clinical trial for TE-EK (Peh et al., 2019), where their TE-EK 
graft with decellularized stromal lamellae as carriers will be assessed 
and applied on humans. 
Other requirements in order to implement a cell-based therapy in 
centers are reproducibility and cost-effectiveness. The new treatment 
should be affordable for health care systems or patients. In addition, the 
new cell-based therapy should have an impact on health equal to or 
better than that of the standard treatment for endothelial dysfunctions. 
CI is clearly less expensive than TE, as neither a carrier nor a long in vitro 
phase are necessary. As far as we know, only one economic analysis of 
TE-EK has been performed. In said study, Tan et al. calculated the cost of 
TE-EK therapy using a collagen sheet and concluded that it would be 
four times cheaper than conventional EK (Tan et al., 2014). 
The selection of an affordable and easily reproducible carrier, such as 
collagen sheets or stromal lamellae from discarded corneas, could 
contribute to decreasing the cost. Moreover, the use of existing equip-
ment routinely used in eye banks, especially in those where EK grafts are 
prepared and delivered and corneal organ cultures are stored, could 
reduce the investment costs. Nevertheless, long-term clinical outcomes 
must be obtained for both cell-based therapies in order to accurately 
assess their overall advantages and disadvantages. 
3. Conclusions and future perspectives 
We are currently closer than ever to offering a real alternative 
treatment for endothelial decompensation. Many successful advances 
have been made in the development of TE-EK grafts and in the perfor-
mance of preclinical TE-EK and CI therapy trials, which have already 
allowed moving on to clinical research. However, further information is 
needed about some aspects of the adaptation of culture protocols to 
GMP, as well as about the economic cost of these cell-based therapies, 
which should be included as additional objective in future studies on 
cell-based therapies. 
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Cueto, L., Meana, Á., Merayo-Lloves, J., 2017. Silk fibroin films for corneal 
endothelial regeneration: transplant in a rabbit descemet membrane endothelial 
keratoplasty. Investig. Ophthalmol. Vis. Sci. 58, 3357–3365. https://doi.org/ 
10.1167/iovs.17-21797. 
Woo, J.H., Ang, M., Htoon, H.M., Tan, D., 2019. Descemet membrane endothelial 
keratoplasty versus descemet stripping automated endothelial keratoplasty and 
penetrating keratoplasty. Am. J. Ophthalmol. 207, 288–303. https://doi.org/ 
10.1016/j.ajo.2019.06.012. 
Xia, X., Atkins, M., Dalal, R., Kuzmenko, O., Chang, K.C., Sun, C.B., Benatti, C.A., Rak, D. 
J., Nahmou, M., Kunzevitzky, N.J., Goldberg, J.L., 2019. Magnetic human corneal 
endothelial cell transplant: delivery, retention, and short-term efficacy. Investig. 
Ophthalmol. Vis. Sci. 60, 2438–2448. https://doi.org/10.1167/iovs.18-26001. 
Yam, G.H.F., Seah, X., Yusoff, N.Z.B.M., Setiawan, M., Wahlig, S., Htoon, H.M., Peh, G.S. 
L., Kocaba, V., Mehta, J.S., 2019. Characterization of human transition zone reveals 
a putative progenitor-enriched niche of corneal endothelium. Cells 8. https://doi. 
org/10.3390/cells8101244. 
Yokoo, S., Yamagami, S., Yanagi, Y., Uchida, S., Mimura, T., Usui, T., Amano, S., 2005. 
Human corneal endothelial cell precursors isolated by sphere-forming assay. 
Investig. Ophthalmol. Vis. Sci. 46, 1626–1631. https://doi.org/10.1167/iovs.04- 
1263. 
Yoshida, J., Oshikata-Miyazaki, A., Yokoo, S., Yamagami, S., Takezawa, T., Amano, S., 
2014. Development and evaluation of porcine atelocollagen vitrigel membrane with 
S. Rodríguez-Fernández et al.                                                                                                                                                                                                                
Experimental Eye Research 207 (2021) 108560
10
a spherical curve and transplantable artificial corneal endothelial grafts. Investig. 
Ophthalmol. Vis. Sci. 55, 4975–4981. https://doi.org/10.1167/iovs.14-14211. 
Yoshida, J., Yokoo, S., Oshikata-Miyazaki, A., Amano, S., Takezawa, T., Yamagami, S., 
2017. Transplantation of human corneal endothelial cells cultured on bio-engineered 
collagen vitrigel in a rabbit model of corneal endothelial dysfunction. Curr. Eye Res. 
42, 1420–1425. https://doi.org/10.1080/02713683.2017.1351568. 
Yoshihara, M., Hayashizaki, Y., Murakawa, Y., 2017. Genomic instability of iPSCs: 
challenges towards their clinical applications. Stem Cell Rev. Reports. https://doi. 
org/10.1007/s12015-016-9680-6. 
Zhang, Y., Cai, S., Tseng, S.C.G., Zhu, Y.T., 2018. Isolation and expansion of multipotent 
progenitors from human trabecular meshwork. Sci. Rep. 8 https://doi.org/10.1038/ 
s41598-018-21098-2. 
Zurawski, C.A., McCarey, B.E., Rij, G., Fernandes, A., 1989. Corneal biometrics of the 
rhesus monkey (Macaca mulatta). J. Med. Primatol. 18, 461–466. https://doi.org/ 
10.1111/j.1600-0684.1989.tb00413.x. 
S. Rodríguez-Fernández et al.                                                                                                                                                                                                                
